All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @_kelsiebeth_ on TikTok · 12s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @_kelsiebeth_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00If no one invests in you, invest in yourself.
  2. 0:06If no one believes in you, believe in yourself.

@_kelsiebeth_'s 6-week semaglutide update, fact-checked

Kelsie Terry

TikTok creator

17.1K viewsWatch on TikTok

Quick answer

The creator describes using semaglutide six weeks postpartum for weight management, framing it as necessary additional support after two pregnancies. Semaglutide (as Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition, but it is not recommended during breastfeeding due to insufficient safety data. At six weeks, the creator is still in the early phase of treatment where side effects are most common and long-term efficacy cannot yet be assessed.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @_kelsiebeth_'s 6-week semaglutide update, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@_kelsiebeth_'s 6-week semaglutide update, fact-checked" from Kelsie Terry. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes using semaglutide six weeks postpartum for weight management, framing it as necessary additional support after two pregnancies.

The reason this review is not generic is the source wording and the canonical claim label "glp1 6 weeks into my semaglutide journey best decision i ve mad." In this clip, the useful excerpt is: "If no one invests in you, invest in yourself." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Six weeks is not enough time to evaluate semaglutide outcomes.
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The creator describes using semaglutide six weeks postpartum for weight management, framing it as necessary additional support after two pregnancies.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator describes using semaglutide six weeks postpartum for weight management, framing it as necessary additional support after two pregnancies. Semaglutide (as Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or 27 with at least one weight-related condition, but it is not recommended during breastfeeding due to insufficient safety data. At six weeks, the creator is still in the early phase of treatment where side effects are most common and long-term efficacy cannot yet be assessed.
  • Semaglutide (Wegovy) produced an average 14.9% body weight reduction vs. 2.4% for placebo over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM) in adults without diabetes.
  • Six weeks is not enough time to evaluate semaglutide outcomes. The STEP trials ran 68 weeks, and side effects including nausea and vomiting peak in the first two months.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Semaglutide (Wegovy) produced an average 14.9% body weight reduction vs. 2.4% for placebo over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM) in adults without diabetes.
  • Six weeks is not enough time to evaluate semaglutide outcomes. The STEP trials ran 68 weeks, and side effects including nausea and vomiting peak in the first two months.
  • Semaglutide is contraindicated during breastfeeding. There is no adequate human data on safety in lactation, and animal studies show drug transfer into milk.
  • The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients, making it more than a cosmetic weight loss drug.
  • Compounded semaglutide is not equivalent to brand-name Wegovy or Ozempic. Purity, dosing accuracy, and safety testing differ, and the FDA has flagged risks with compounded versions.
  • Postpartum weight retention of more than 5kg at one year significantly increases long-term obesity risk (Nehring et al., 2011, Obesity Reviews), which does contextualize why someone might seek medical intervention.
  • GLP-1 receptor agonists require a prescription and ongoing medical supervision. Anyone considering this medication based on social media content should consult a licensed clinician before starting.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @_kelsiebeth_ actually say?

Honestly? Not much, medically speaking. The creator said, "If no one invests in you, invest in yourself. If no one believes in you, believe in yourself." That's motivational content, not a medical claim. Her caption does the heavier lifting: six weeks into semaglutide, postpartum context, describing it as the "best decision" and framing it as "extra help" after two pregnancies.

There are no dosing claims, no cure claims, no wild before-and-after promises. Just a person sharing a personal experience through an inspirational lens. The medical content lives almost entirely in the caption and hashtags, not the spoken words. That context matters when fact-checking, because we should evaluate what was actually said versus what viewers might infer.

Does the science back this up?

The general premise, that semaglutide can help with weight loss when diet and lifestyle alone aren't enough, is well-supported. This isn't fringe wellness content.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) followed 1,961 adults on 2.4mg weekly semaglutide versus placebo. Participants lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group. That's a meaningful difference, not a rounding error. The STEP 2 trial confirmed similar results in adults with type 2 diabetes, though with slightly lower weight loss percentages.

Postpartum weight retention is also a legitimate clinical concern. Research published in Obesity Reviews (Nehring et al., 2011) found that retaining more than 5kg one year after delivery significantly increased long-term obesity risk. Using a GLP-1 receptor agonist in that context isn't medically outrageous, though eligibility depends on factors like breastfeeding status, BMI, and comorbidities that a video can't verify.

What did they get wrong (or right)?

Credit where it's due: she didn't oversell this. There are no promises of rapid transformation, no specific numbers thrown around, no claims about what semaglutide "does" to your metabolism. She framed it as personal help, not a universal fix. That's more restrained than a lot of GLP-1 content on this platform.

What's missing, though, matters. The caption calls it the "best decision" with no acknowledgment of the side effect profile. Nausea, vomiting, gastroparesis risk, and pancreatitis concerns aren't minor footnotes. The FDA label for Wegovy includes a boxed warning about thyroid C-cell tumors in rodent studies, though human relevance remains unclear. Viewers in similar postpartum situations watching this might not know that semaglutide is contraindicated during breastfeeding. That omission, combined with the aspirational framing, is where the content becomes subtly misleading, not through false claims, but through incomplete ones.

What should you actually know?

Semaglutide is a legitimate, FDA-approved medication for chronic weight management (Wegovy, approved 2021) and type 2 diabetes (Ozempic, approved 2017). It is not a supplement, a hack, or a trend. It requires a prescription and medical supervision for good reasons.

The postpartum angle deserves specific attention. If someone is breastfeeding, semaglutide is not recommended. There is no adequate safety data in lactating individuals, and animal studies show it passes into milk. Anyone in a postpartum situation considering this medication needs a direct conversation with a licensed clinician, not a TikTok video as a starting point.

Six weeks is also early. The STEP trials ran 68 weeks. Side effects often peak in weeks two through eight. Judging semaglutide as the "best decision" at six weeks is like reviewing a restaurant after the appetizers. Results at that stage can feel dramatic, but long-term adherence, weight regain after stopping, and cardiovascular outcomes (the SELECT trial, Lincoff et al., 2023, NEJM, showed 20% reduction in major cardiac events) are the more meaningful data points.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kelsie Terry · TikTok creator

17.1K views on this video

6 weeks into my semaglutide journey ✨ best decision I’ve made after having two babies and just need that extra help #semiglutide #glp1forweightloss #weightloss #fitnessjourney

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide (wegovy) produced an average 14.9% body weight reduction vs.?

Semaglutide (Wegovy) produced an average 14.9% body weight reduction vs. 2.4% for placebo over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM) in adults without diabetes.

What does the video say about six weeks?

Six weeks is not enough time to evaluate semaglutide outcomes. The STEP trials ran 68 weeks, and side effects including nausea and vomiting peak in the first two months.

What does the video say about semaglutide?

Semaglutide is contraindicated during breastfeeding. There is no adequate human data on safety in lactation, and animal studies show drug transfer into milk.

What does the video say about the select trial (lincoff et al., 2023, nejm) found semaglutide?

The SELECT trial (Lincoff et al., 2023, NEJM) found semaglutide reduced major adverse cardiovascular events by 20% in high-risk patients, making it more than a cosmetic weight loss drug.

What does the video say about compounded semaglutide?

Compounded semaglutide is not equivalent to brand-name Wegovy or Ozempic. Purity, dosing accuracy, and safety testing differ, and the FDA has flagged risks with compounded versions.

What does the video say about postpartum weight retention of more than 5kg at one year?

Postpartum weight retention of more than 5kg at one year significantly increases long-term obesity risk (Nehring et al., 2011, Obesity Reviews), which does contextualize why someone might seek medical intervention.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kelsie Terry, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.